Cameroon vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Access to anti-retroviral drugs, female

Cameroon
95.0%
in 2024
Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
38.4%
in 2024
Cameroon rank
19th
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank
18th

Access to anti-retroviral drugs, female over time

  • Cameroon
  • Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
020406080100200020122024

How they compare

Cameroon currently reports 95.0% against 38.4% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), a difference of 56.6%.

That makes Cameroon's figure about 2.5 times Middle East, North Africa, Afghanistan & Pakistan (excluding high income)'s.

The two have swapped places 1 time across 25 shared years of data; in 2000 it was Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ahead.

Cameroon ranks 19th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th of 141 countries.

Cameroon has averaged higher in every one of the 3 decades both report.

Head to head by decade

Decade Cameroon Middle East, North Africa, Afghanistan & Pakistan (excluding high income) Difference Ahead
2000s 4.2% 3.8% 0.4% Cameroon
2010s 38.0% 20.3% 17.7% Cameroon
2020s 86.6% 34.3% 52.3% Cameroon

Averages of every year both report within each decade.

Frequently asked questions

Which has higher access to anti-retroviral drugs, female, Cameroon or Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
Cameroon, at 95.0% against 38.4% in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) as of 2024.
What is the difference in access to anti-retroviral drugs, female between Cameroon and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
56.6%, with Cameroon ahead.
How many years of comparable data are there for Cameroon and Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
25 years are reported by both, from 2000 to 2024.
How do Cameroon and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank globally for access to anti-retroviral drugs, female?
Cameroon ranks 19th and Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 18th of 141 countries.
Where does this data come from?
UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Cameroon vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Access to anti-retroviral drugs, female. Statizoid, drawing on UNAIDS estimates. Retrieved 18 September 2026, from https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-female-percent/cameroon/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/compare/access-to-anti-retroviral-drugs-female-percent/cameroon/middle-east-north-africa-afghanistan-and-pakistan-excluding-high-income/">Cameroon vs Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Access to anti-retroviral drugs, female</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.